Forrest N. Gamble, MD
Student in an Organized Health Care Education/Training Program
At a glance
- In the NPI registry since
- 2020
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2020Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
- Student in an Organized Health Care Education/Training Program primary
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 1 companies. The companies reported $270 in research payments for these studies, mostly to the institutions running them.
- A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Eli Lilly and Company · Active, not recruiting · NCT04965493 - A phase 3 open-label, randomized study of LOXO-305 versus investigator choice of btk inhibitor in patients with previously treated btk inhibitor naive mantle cell lymphoma (bruin MCL-321)
Eli Lilly and Company - Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Eli Lilly and Company · Active, not recruiting · NCT04666038 - A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Eli Lilly and Company · Active, not recruiting · NCT05023980
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.